AVAH.NASDAQAveanna Healthcare Holdings, INC
DEF: Aveanna Healthcare Reports Strong 2025, Completes Transformation
Sentiment:
Proxy Statement
Aveanna Healthcare Holdings Inc. announces strong fiscal year 2025 results, including significant revenue and Adjusted EBITDA growth, completion of its Strategic Transformation, and a major debt refinancing.
Capital raiseCompleted a significant refinancing of its credit facility in 2025, which simplified the capital structure, extended maturities, and increased liquidity.Certain selling stockholders affiliated with J.H. Whitney Capital Partners sold 10,000,000 shares of the company's common stock in an underwritten offering on October 21, 2025.An additional 1,500,000 shares of the company's common stock were sold on October 28, 2025, following the full exercise of an over-allotment option by J.H. Whitney Capital Partners affiliates.
Better than expectedFiscal year 2025 revenue grew by 20.2% to $2.433 billion.Adjusted EBITDA increased by 74.8% to $320.9 million.Net cash provided by operating activities was $125.9 million, and free cash flow was $131.0 million.The company achieved net income in fiscal year 2025 ($225,034) after reporting net losses in fiscal years 2023 and 2024.
Summary
- Fiscal year 2025 revenue reached approximately $2.433 billion, representing a substantial 20.2% year-over-year growth.
- Adjusted EBITDA for fiscal year 2025 was $320.9 million, reflecting a significant 74.8% year-over-year growth.
- Net cash provided by operating activities was $125.9 million, and free cash flow was $131.0 million for fiscal year 2025.
- The company successfully completed its three-year Strategic Transformation strategy, finalizing modernization efforts across Private Duty Services, Home Health and Hospice, and Medical Solutions.
- Aveanna completed the acquisition and integration of Thrive Skilled Pediatric Care, expanding its footprint and specialized care model into two new states.
- A comprehensive debt refinancing was completed in 2025, which simplified the capital structure, extended maturities, increased liquidity, and strengthened the balance sheet.
- The company announced an agreement to acquire Family First Homecare, signaling continued expansion.
- The Annual Meeting of Stockholders is scheduled for May 29, 2026, to elect three Class II director nominees, ratify the appointment of Ernst & Young LLP as independent registered public accountants, and approve executive compensation on an advisory basis.
Sentiment
Score: 8
Explanation: StockSavvy.ai views this as a highly positive filing, reflecting strong financial performance, successful strategic execution, and a strengthened financial position, indicating robust operational health and future growth potential.
Positives
- Exceptional financial results in fiscal year 2025, with revenue growing 20.2% to $2.433 billion and Adjusted EBITDA increasing 74.8% to $320.9 million.
- Strong cash generation, with net cash provided by operating activities at $125.9 million and free cash flow at $131.0 million.
- Successful completion of the three-year Strategic Transformation strategy, enhancing operational efficiency and resilience.
- Strategic acquisition and integration of Thrive Skilled Pediatric Care, expanding geographic reach and specialized care offerings.
- Transformative debt refinancing that simplified the capital structure, extended maturities, increased liquidity, and strengthened the balance sheet.
- Continued strategic growth through new acquisitions, as evidenced by the announced agreement to acquire Family First Homecare.
- Stockholders overwhelmingly approved the executive compensation in the May 9, 2025, annual meeting, indicating strong investor confidence in compensation practices.
Negatives
- One Form 3 reporting initial beneficial ownership for director nominee Sam Weil was inadvertently filed late on March 18, 2026, due to administrative error.
- The company reported net losses in fiscal years 2023 and 2024, although it returned to net income in fiscal year 2025.
Risks
- Risks related to compensation policies and practices affecting senior management, though the company believes its governance policies and compensation structure mitigate this.
- Cybersecurity threats, which are managed by a dedicated Assistant Vice President of Cybersecurity under the ultimate oversight of the Audit Committee.
- Operational and regulatory challenges inherent in the homecare industry.
- Potential for loss of tax deductibility under Section 280G of the U.S. Internal Revenue Code and imposition of excise taxes under Section 4999 of the Code on excess parachute payments in the event of a change in control.
Future Outlook
The company is positioned for sustainable growth, operating efficiency, and long-term value creation, focusing on scale, efficiency, innovation, and continued leadership in home and community-based care. It also plans to pursue new acquisitions, such as the recently announced agreement to acquire Family First Homecare, to expand services and impact.
Management Comments
- "We remain focused on our Aveanna Mission: to revolutionize the way homecare is delivered, one patient at a time."
- "Fiscal year 2025 was a critical and defining year for Aveanna."
- "We delivered exceptional financial results, finalized modernization efforts across all lines of business, completed the acquisition and integration of Thrive Skilled Pediatric Care, and meaningfully strengthened our balance sheet through a comprehensive debt refinancing."
- "As we exit 2025, these modernization efforts are largely complete, providing Aveanna with a more scalable, efficient, and resilient operating platform."
- "The addition of Thrive strengthens our footprint in existing states while also introducing Aveannas specialized care model into two new states, expanding access to high-quality, in-home pediatric care for more medically complex children and their families."
- "This refinancing simplified our capital structure, extended maturities, increased liquidity, and strengthened our balance sheet."
- "The foundation it created enables the next phase of growth, one focused on scale, efficiency, innovation, and continued leadership in home and community-based care."
- "I am incredibly proud of the Aveanna team, our caregivers, clinicians, and employees, whose dedication makes our mission possible."
Industry Context
StockSavvy.ai notes that Aveanna's strong performance and strategic acquisitions like Thrive Skilled Pediatric Care and Family First Homecare demonstrate a robust expansion strategy within the growing homecare market, particularly in specialized pediatric care. The focus on operating efficiencies and technology investments aligns with broader industry trends towards value-based care and digital transformation in healthcare delivery.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Legal Officer and Secretary | NA | Jerry Perchik | April 2024 | Appointment |
| Class III Director | Sheldon M. Retchin, M.D., M.S.P.H | NA | March 27, 2025 | Resignation |
| Class II Director | NA | Sam Weil | 2025 | Appointment |
| Class II Director | Christopher R. Gordon | NA | November 13, 2025 | Resignation |
| Class III Director | NA | Brent Layton | November 2024 | Appointment |
| Class I Director | Robert M. Williams, Jr. | NA | February 27, 2026 | Resignation |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Composition | The Board is separated into three classes (Class I, II, III) with staggered three-year terms, with approximately one-third elected annually. The Board is composed of eight directors. | NA | Provides stability and may delay or prevent changes in control. |
| Board Leadership Structure | The roles of Chairman (Rodney D. Windley) and Chief Executive Officer (Jeff Shaner) are separated. | NA | Enhances independent oversight and strategic focus. |
| Director Independence | Seven out of eight directors (Rodney D. Windley, Victor F. Ganzi, Sam Weil, Brent Layton, Devin OReilly, Steven E. Rodgers, and Erica Schwartz) are independent as defined by Nasdaq rules. | NA | Strengthens independent oversight, although the company is a controlled company. |
| Controlled Company Exemption | The company avails itself of the Nasdaq controlled company exemption for the Nominating and Corporate Governance Committee, meaning it is not composed entirely of independent directors. | NA | Allows for greater influence by principal stockholders (Bain Capital and J.H. Whitney) in director nominations. |
| Board Committees | Established Audit, Compensation, Nominating and Corporate Governance, and Clinical Quality Committees, each operating under a Board-approved charter. | NA | Provides specialized oversight for financial reporting, executive compensation, governance, and clinical compliance. |
| Stock Ownership Guidelines | Implemented stock ownership guidelines for non-employee directors (4x annual cash retainer) and Named Executive Officers (CEO: 6x base salary; Other NEOs: 3x base salary), with a five-year compliance period. | NA | Aligns the financial interests of leadership and non-employee directors with stockholders, promoting long-term value creation. |
| Securities Trading Policy | Prohibits directors, officers, employees, and related parties from hedging, short sales, trading in publicly traded put/call options, purchasing on margin, borrowing against, or pledging company securities. | NA | Designed to promote compliance with insider trading laws and prevent speculative or risky trading practices. |
| Code of Ethical Business Conduct | Adopted a written code of business conduct and ethics applicable to directors, officers, and employees. | NA | Establishes high standards of ethics, integrity, professionalism, and compliance across the organization. |
Related Party Transactions
- Stockholders Agreement: The Amended and Restated Stockholders Agreement (A&R Stockholders Agreement) grants Sponsor Affiliates (Bain Capital and J.H. Whitney) rights to designate directors based on their ownership percentage.
- Registration Rights Agreement: The Amended and Restated Registration Rights Agreement (A&R Registration Rights Agreement) grants certain Sponsor Affiliates the right to require the company to file registration statements for the sale of common stock and piggyback registration rights.
- Revenue Cycle Software Agreements: Subsidiaries are party to software agreements with ZirMed, Inc. d/b/a Waystar, in which affiliates of Bain Capital held a controlling interest prior to October 2019 and currently hold a minority position. Payments to Waystar were approximately $0.4 million for the fiscal year ended January 3, 2026.
Stakeholder Impact
- Shareholders: Strong financial performance, strategic acquisitions, and debt refinancing are expected to create long-term value. The say-on-pay vote allows shareholders to influence executive compensation. Director elections and auditor ratification are key governance matters.
- Employees: The Aveanna Healthcare Relief Fund provides financial assistance for unexpected emergencies. Employee engagement, fostering culture, and leadership development are human capital objectives. Equity incentive plans and employee stock purchase plans are used for attraction, retention, motivation, and reward.
- Patients/Families: The acquisition of Thrive Skilled Pediatric Care expands access to high-quality, in-home pediatric care for medically complex children. The company's mission is to revolutionize homecare delivery.
- Creditors: The debt refinancing strengthened the balance sheet, extended maturities, and increased liquidity, which is positive for creditors.
Next Steps
- Annual Meeting of Stockholders on May 29, 2026, to elect three Class II director nominees.
- Ratification of Ernst & Young LLP as independent registered public accountants for the fiscal year ending January 2, 2027.
- Advisory, non-binding vote on the compensation paid to Named Executive Officers.
- Consideration of any other business properly presented at the Annual Meeting.
- Continued pursuit of new acquisitions, such as the recently announced agreement to acquire Family First Homecare.
- Next required vote on the frequency of future executive compensation votes no later than the annual meeting of stockholders in 2028.
Key Dates
| Date | Description |
|---|---|
| 2017-03-16 | The Company and Sponsor Affiliates entered into the Original Stockholders Agreement. |
| 2021-04-28 | The 2021 Stock Incentive Plan became effective. |
| 2021-09-01 | Deborah Stewart joined Aveanna as Vice President and Chief Accounting Officer. |
| 2023-01-01 | Jeff Shaner's appointment as Chief Executive Officer became effective. |
| 2023-07-01 | Matthew Buckhalter began serving as Interim Chief Financial Officer. |
| 2023-12-31 | Information as of this date for Nut Tree Capital Management, LP 13G filing. |
| 2024-01-01 | Matthew Buckhalter was appointed Chief Financial Officer. |
| 2024-02-14 | Nut Tree Capital Management, LP 13G filing date. |
| 2024-04-01 | Definitive proxy statement on Schedule 14A filed with the SEC. |
| 2024-04-01 | Jerry Perchik joined Aveanna as Chief Legal Officer and Secretary. |
| 2024-11-01 | Brent Layton joined the Board of Directors. |
| 2025-02-14 | Performance awards originally issued on February 14, 2022, were modified, and new LTI grant for fiscal year 2025 was approved. |
| 2025-03-25 | Definitive proxy statement on Schedule 14A filed with the SEC. |
| 2025-03-27 | Dr. Sheldon M. Retchin resigned as a Class III Director. |
| 2025-05-09 | Annual meeting of stockholders where the advisory say on pay vote occurred. |
| 2025-06-06 | Amendment to the A&R Stockholders Agreement. |
| 2025-10-21 | Certain selling stockholders affiliated with J.H. Whitney Capital Partners sold 10,000,000 shares of common stock in an underwritten offering. |
| 2025-10-28 | Certain selling stockholders affiliated with J.H. Whitney Capital Partners sold an additional 1,500,000 shares of common stock following the full exercise of an over-allotment option. |
| 2025-11-13 | Christopher R. Gordon resigned as a Class II Director, and an amendment to the A&R Stockholders Agreement was made. |
| 2025-12-31 | Information as of this date for J.H. Whitney Equity Partners VII 13G/A filing. |
| 2026-01-01 | 4,219,927 shares of common stock were added to the 2021 Plan pursuant to the evergreen provision. |
| 2026-01-02 | Fiscal year ending date for which Ernst & Young LLP is appointed independent registered public accountants. |
| 2026-01-03 | Fiscal year 2025 ended on this date. Equity compensation plan information is as of this date. |
| 2026-01-04 | 1,801,642 shares of common stock were added to the ESPP pursuant to the evergreen provision. |
| 2026-02-10 | J.H. Whitney Equity Partners VII 13G/A filing date. |
| 2026-02-14 | Bain Capital Investors, LLC 13G filing date. |
| 2026-02-17 | New employment agreements became effective with Named Executive Officers. |
| 2026-02-27 | Robert M. Williams, Jr. resigned as a Class I Director. |
| 2026-03-18 | Sam Weil's initial beneficial ownership Form 3 was inadvertently filed late. |
| 2026-03-19 | Annual Report on Form 10-K for the fiscal year ended January 3, 2026, was filed with the SEC. |
| 2026-03-27 | Fiscal year 2025 non-equity incentive compensation payments were made. |
| 2026-04-06 | Record Date for determining stockholders entitled to vote at the Annual Meeting. |
| 2026-04-17 | Notice of Annual Meeting and Proxy Statement dated. Notice of Internet Availability of Proxy Materials, Proxy Statement, and form of proxy distributed and made available on the Internet. |
| 2026-05-19 | Deadline for requesting a printed copy of proxy materials. List of stockholders entitled to vote will be available at corporate headquarters. |
| 2026-05-29 | Date of the Annual Meeting of Stockholders. |
| 2026-12-18 | Deadline for stockholder proposals for the 2027 Annual Meeting to be included in the proxy statement. |
| 2027-01-29 | Earliest date for stockholder notice of intention to introduce a nomination or propose an item of business at the 2027 Annual Meeting. |
| 2027-02-26 | Latest date for stockholder notice of intention to introduce a nomination or propose an item of business at the 2027 Annual Meeting. |
| 2027-03-30 | Deadline for stockholder nominees for directors to be considered timely for inclusion on a universal proxy card pursuant to Rule 14a-19. |
| 2028-01-01 | Terms of Class I directors expire at the annual meeting of stockholders to be held in this year. |
| 2028-05-09 | Latest date for the next required vote on the frequency of future executive compensation votes. |
| 2029-01-01 | Terms of Class II directors expire at the annual meeting of stockholders to be held in this year. |
Recommendation
strong buyThe company demonstrated exceptional financial performance in fiscal year 2025 with substantial revenue and Adjusted EBITDA growth, coupled with positive free cash flow. The successful completion of its Strategic Transformation, the accretive acquisition of Thrive Skilled Pediatric Care, and a transformative debt refinancing significantly strengthen its operational platform and financial health. The announced agreement to acquire Family First Homecare signals continued strategic expansion. These factors, combined with a clear future outlook focused on growth and efficiency, make Aveanna Healthcare a compelling investment opportunity.
Keywords
Homecare, Healthcare, Pediatric Care, Hospice, Medical Solutions, SEC Filing, Proxy Statement, Financial Results, Adjusted EBITDA, Revenue Growth, Debt Refinancing, Acquisitions, Corporate Governance, Executive Compensation, Stockholder Meeting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.